Finnegan Neonatal Abstinence Score (NAS) Calculator
The Modified Finnegan Neonatal Abstinence Score (NAS) is the most widely used clinical tool for assessing opioid withdrawal in newborns. Select the observed severity for each of the 21 signs across the three domains below. The total score updates instantly, and you get clinical guidance on treatment thresholds, monitoring intervals, and what the number means.
What is the Finnegan Neonatal Abstinence Score?
The Finnegan Neonatal Abstinence Score (FNAS), also called the Modified Finnegan Neonatal Abstinence Scoring Tool (FNAST), is the most widely used standardized instrument for assessing opioid withdrawal in newborns. Developed by Loretta Finnegan in the 1970s and subsequently refined, the tool quantifies 21 observable signs across three physiological domains: central nervous system disturbances, metabolic/vasomotor/respiratory disturbances, and gastrointestinal disturbances. The sum of all 21 items produces a total score between 0 and 43, with higher values reflecting more severe withdrawal. It is used in neonatal intensive care units (NICUs) and nurseries worldwide to guide decisions about when to begin, titrate, and wean pharmacological treatment for neonatal abstinence syndrome (NAS), also called neonatal opioid withdrawal syndrome (NOWS).
How to perform a Finnegan assessment
Assessments should be performed approximately 30 to 60 minutes after a feeding, ideally while the infant is awake and calm but before the next feeding begins. The first assessment is typically done within the first 2 hours of life for an at-risk infant, with subsequent assessments every 4 hours. If the score reaches 8 or above, the monitoring interval is shortened to every 2 hours for at least 24 hours. Standard practice calls for two nurses to score independently when possible, as interrater variability is a recognized limitation of the tool. Each of the 21 signs is observed and scored according to the most severe manifestation seen during the entire assessment interval, not just at the moment of observation. All scores should be documented in the medical record, and the running trend across serial assessments is at least as important as any single score.
Treatment thresholds and pharmacological management
Pharmacological treatment is generally initiated when: (1) two consecutive Finnegan scores are 12 or above, or (2) three consecutive scores are 8 or above. These thresholds represent the consensus in most institutional protocols, though individual hospitals may use slight variations. When pharmacological treatment is indicated, oral morphine solution and oral methadone are the most commonly used first-line agents in North American and European centres. Non-pharmacological care, including swaddling, a low-stimulation environment, skin-to-skin (kangaroo) care, breastfeeding where eligible, and pacifier use, is recommended for all infants with NAS regardless of score, and is the sole treatment for infants with low scores. Weaning from pharmacological treatment is guided by serial Finnegan scores decreasing and remaining below threshold levels.
Limitations of the Finnegan scoring system
The Finnegan score has known limitations that clinicians should keep in mind. Interrater reliability can be variable, particularly for subjective signs such as cry quality, tremor severity, and muscle tone. The tool was originally designed for full-term infants born to mothers using heroin; its validity in preterm infants or those with iatrogenic (medically induced) withdrawal is less established. Because some signs overlap with other neonatal conditions, such as hypoglycaemia, infection, or central nervous system injury, the score must always be interpreted in the clinical context of the infant. Newer tools like the Eat, Sleep, Console (ESC) approach have emerged as potential alternatives that emphasize functional ability rather than symptom counting, though the Finnegan score remains the reference standard in most centres worldwide.
Finnegan Score clinical interpretation and action thresholds
| Score range | Severity | Monitoring interval | Clinical action |
|---|---|---|---|
| 0-3 | Minimal signs | 4 hours | Routine NAS monitoring; non-pharmacological care |
| 4-7 | Mild withdrawal | 4 hours | Intensify non-pharmacological measures; close observation |
| 8-11 | Moderate withdrawal | 2 hours for >= 24 hrs | 3 consecutive scores >= 8 trigger treatment review |
| 12+ | Severe withdrawal | 2 hours | 2 consecutive scores >= 12: initiate pharmacological treatment |
Based on the Modified Finnegan Neonatal Abstinence Scoring Tool (FNAST). Treatment thresholds may vary by institution.
Frequently asked questions
What is a normal Finnegan score for a newborn?
A score of 0 to 3 indicates minimal or no signs of withdrawal and is generally considered within the range expected for a healthy newborn. Scores in this range require only routine monitoring and non-pharmacological comfort care. Any score of 4 or above warrants closer attention and documentation of trends across serial assessments.
At what score is pharmacological treatment started?
Pharmacological treatment is typically initiated when either two consecutive Finnegan scores are 12 or above, or three consecutive scores are 8 or above. A single elevated score alone is not sufficient to trigger drug treatment; it is the pattern across serial assessments that guides clinical decision-making. The exact threshold can also vary by institution and attending physician judgement.
How often should the Finnegan score be measured?
The first assessment is performed within the first 2 hours of birth for at-risk infants, then every 4 hours (timed 30-60 minutes after each feeding) under standard conditions. If the score reaches 8 or above, the interval shortens to every 2 hours and remains at that frequency for at least 24 hours. The 4-hour interval can be resumed once scores have remained below 8 for 24 consecutive hours on the 2-hour schedule.
What is the difference between NAS and NOWS?
Neonatal Abstinence Syndrome (NAS) is the broader term for withdrawal symptoms in a newborn following cessation of any substance the infant was exposed to in utero, including opioids, benzodiazepines, SSRIs, and alcohol. Neonatal Opioid Withdrawal Syndrome (NOWS) is the more specific term used when opioids are the primary substance involved. The Finnegan score was designed primarily for opioid-related withdrawal, which accounts for the large majority of NAS cases in clinical practice.
Can breastfeeding reduce the Finnegan score?
Yes, breastfeeding is associated with lower Finnegan scores and reduced need for pharmacological treatment in eligible infants. Breast milk provides small amounts of opioids (when the mother is on opioid maintenance therapy such as methadone or buprenorphine), which may reduce withdrawal severity. Breastfeeding also provides warmth, comfort, and non-nutritive sucking, all of which are known to attenuate withdrawal signs. Breastfeeding is encouraged unless there are specific contraindications such as HIV or illicit polysubstance use.
Is the Finnegan score the same as the modified Finnegan score?
The original Finnegan scoring tool from the 1970s had some differences from the version in common use today. The modified or simplified versions, including the Modified Finnegan Neonatal Abstinence Score used by MDCalc and many hospitals, score 21 signs for a maximum of 43 points, compared to the original 31-item version. The core clinical domains and treatment thresholds are the same across versions. This calculator uses the 21-item modified version that is most widely used in clinical practice.